Videos

A brief discussion elucidating the patient and caregiver perspectives when selecting a treatment option for renal cell carcinoma.

Alexander Lesokhin, MD, presents data from an interim analysis of the GMMG-CONCEPT trial investigating an isatuximab-based quadruplet regimen for high-risk NDMM.

The panel reviews possible treatment approaches for patients with high-risk NDMM, and how MRD negativity affects their decision making.

Myeloma experts give an overview of allogeneic CAR T-cell therapy and other technology advances in MM.

Noa Biran, MD, and David Siegel, MD, discuss how CAR T-cell availability has impacted the field of multiple myeloma.

An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.

Experts on graft-vs-host disease review GVHD and methods of prophylaxis preceding transplant.

Hope S. Rugo, MD, FASCO, and Paolo Tarantino, MD, offer closing remarks on the growing field of HER2-low and triple-negative breast cancer.

A panel of experts and a patient with graft-vs-host disease discuss the relationship between transplantation and GVHD.

Breast cancer experts talk through their approaches to treating HER2-low triple-negative breast cancer.

The panel wraps up their discussion with a review of how they would approach treating frontline non-clear cell RCC.

The panel shares how they would treat a patient with advanced RCC after disease progression on adjuvant pembrolizumab.

Tian Zhang, MD, explains whether recent data from ESMO 2022 has changed their approach to adjuvant immune therapy in advanced RCC.

The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.

Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.

Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.

The panel shares some closing thoughts on ctDNA testing in patients with colorectal cancer.

The panel comments on how they see ctDNA assay usage evolving in colorectal cancer management.

Comprehensive insight on how best to communicate potential adverse events and followup strategies with patients going on therapy for RCC.

Hans Hammers, MD, PhD, provides a broad overview on the treatment options available to patient who receive a diagnosis of renal cell carcinoma.

Sandy Wong, MD, presents data from a subgroup analysis of the GRIFFIN and MASTER trials in patients with transplant-eligible NDMM.

Drs Lesokhin and Wong detail their strategies for maintenance therapy after transplant in NDMM treatment.

Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.

Experts on multiple myeloma discuss available BCMA-targeted CAR T-cell therapies and the KarMMa and CARTITUDE-1 clinical trials.

Noa Biran, MD, and David Siegel, MD, review the shifting treatment paradigms in multiple myeloma (MM).

Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.

Experts on breast cancer give an overview to treating PD-L1-positive triple-negative breast cancer.

Hope S. Rugo, MD, FASCO, discusses how BRCA mutations change the treatment approach for triple-negative breast cancer.

The panel continues their discussion of investigational triplet therapies in frontline RCC treatment.

Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.